Laboratory supplies: consolidating the consumables spend, standardising the specification first, treating laboratory consumables as items with a named part number rather than as a category, and keeping a second source for what stops work

Consumables are where a laboratory's money quietly goes, and they are also where the largest easy savings are, because the items are close to interchangeable at a given specification and most laboratories buy them without one. The order of operations matters: standardise the specification, then consolidate, then negotiate. Doing it the other way round buys cheaper items that do not work. This page covers the sequence and the exceptions.

the OSHA laboratory standard requiring a written chemical hygiene plan
1910.1450
hazard communication, which decides what a container must tell the user
1910.1200
the CDC and NIH handbook that sets biosafety levels and containment practice
BMBL

Figures in this panel are the standards this class of equipment is specified and inspected against, named from the regulations themselves and linked in the sources below. They are identifiers, not prices: BioBricks publishes verified prices for synthesis services only, and does not claim an equipment price index it has not measured.

The sequence that works

  1. Write the specification before chasing price. For each routine item, record what actually matters: material, sterility, certification, dimensions and any compatibility with equipment. Most laboratory arguments about a cheaper supplier are really arguments about an unwritten specification that the new item failed.
  2. Consolidate onto fewer suppliers. Fewer suppliers means better pricing, fewer deliveries, fewer invoices and less administration, and it is usually worth more than the last increment of unit price. Consolidation also gives the laboratory leverage it does not have when spend is scattered.
  3. Keep a second source for what stops work. For anything whose absence halts work, qualify a second product and keep it qualified. Supply disruption is a routine event rather than an emergency, and the laboratories that cope are the ones that qualified an alternative before they needed it.
  4. Hold stock where the lead time is long. Consumables with long or unreliable lead times justify holding stock even at a storage cost. Consumables with short lead times do not, and holding them ties up money and expires on the shelf.
  5. Watch the specification creep. Laboratories accumulate premium specifications that nobody chose deliberately: certified nuclease-free tubes for buffer work, the highest purity solvent for a wash step. A periodic review of what is actually required against what is actually ordered usually finds real money.

What not to consolidate

Anything qualified into a validated method stays where it is until a change is assessed and documented, however attractive the alternative price. The cost of requalifying a method exceeds the consumable saving in almost every case.

The same applies to items whose performance is hard to test quickly, such as certified nuclease-free plastics, where a problem is discovered as a failed experiment weeks later rather than at goods-in.

Goods-in, storage and labelling

Check deliveries against the specification rather than the order line, keep certificates where they can be found, and store consumables dry, off the floor and away from anything that punctures packaging. Sterility claims apply only to intact packaging.

Chemical containers must communicate their hazards, and working containers decanted from stock are the ones most often unlabelled. The laboratory's chemical hygiene plan should say plainly how that is handled.

Common questions

How do I reduce laboratory supplies spend?
Write specifications for routine items first, then consolidate onto fewer suppliers, then negotiate. Chasing price before specifying is how laboratories buy cheaper items that do not work.
Should we use a single supplier?
Consolidation is usually worth more than the last increment of unit price, but keep a qualified second source for anything whose absence stops work. Supply disruption is routine rather than exceptional.
Can we switch a consumable used in a validated method?
Not without assessing and documenting the change. Requalifying a method almost always costs more than the consumable saving, so validated items are the wrong place to look for savings.
How much stock should we hold?
Hold stock where lead times are long or unreliable and the item stops work. Do not hold stock of short lead time items, which ties up money and expires on the shelf.

Get a shortlist for your project

Free. We send a shortlist of vendors whose published prices and service scope fit what you described, built from the verified index on this site. We may email you about this enquiry and similar services from this site; opt out any time, including from the first message.

Browse by service class

Sources

Cite or embed this figure

The median advertised gene synthesis price per base pair in the US research synthesis services market was $0.11 in August 2026, across 4 verified vendor service pages recorded in BioBricks Synthesis Price Index.

Cite as: "BioBricks Synthesis Price Index", updated 2026-08-24, https://biobricks.org/laboratory-supplies/.

Embed this figure (plain HTML, no scripts)
median advertised gene synthesis price per base pair · the US research synthesis services market · August 2026

$0.11

Middle 50%$0.07 – $0.15
verified vendor service pages4

Source: BioBricks Synthesis Price Index

Get a vendor shortlistCompare synthesis prices